(Q37697795)

22 August 2017

1 reference

title

5-Lipoxygenase inhibitors: a review of recent developments and patents (English)

1 reference

22 August 2017

0 references

2

Oliver Werz

1 reference

22 August 2017

Carlo Pergola

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Therapeutic Patents

22 August 2017

published in

1 reference

22 August 2017

volume

20

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

355-375

1 reference

Leukotrienes and lipoxins: structures, biosynthesis, and biological effects

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

5-Oxo-ETE and the OXE receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Expanding roles for leukotrienes in airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Endothelium-dependent vascular responses induced by leukotriene B4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Leukotrienes as mediators of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Additional functions for the cysteinyl leukotrienes recognized through studies of inflammatory processes in null strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Neutrophil-derived leukotriene B4 is required for inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

5-lipoxygenase-derived leukotrienes: mediators also of atherosclerotic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Association between 5-lipoxygenase expression and plaque instability in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Leukotriene modifiers in the treatment of cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Therapeutic options for 5-lipoxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

5-Lipoxygenase: regulation of expression and enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

5-Lipoxygenase expression in Langerhans cells of normal human epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Glucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

5-Lipoxygenase: Cellular Biology and Molecular Pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Effect of sex hormones on eosinophilic inflammation in nasal mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Therapeutic implications of sex differences in asthma and atopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Structural characterization of the catalytic domain of the human 5-lipoxygenase enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Caspase-mediated degradation of human 5-lipoxygenase in B lymphocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation of 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

5-Lipoxygenase interacts with coactosin-like protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Designing therapeutically effective 5-lipoxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Inhibitors of the 5-lipoxygenase pathway in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Development of 5-lipoxygenase inhibitors--lessons from cellular enzyme regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Synthesis and 5-lipoxygenase inhibitory activity of new cinnamoyl and caffeoyl clusters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Synthesis and biological evaluation of 1-(benzenesulfonamido)-2-[5-(N-hydroxypyridin-2(1H)-one)]acetylene regioisomers: a novel class of 5-lipoxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Substituted coumarins as potent 5-lipoxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Licofelone: the answer to unmet needs in osteoarthritis therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Celecoxib inhibits 5-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Biological evaluation of 2-(4-amino-phenyl)-3-(3,5-dihydroxylphenyl) propenoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Design and synthesis of novel 2-amino-5-hydroxyindole derivatives that inhibit human 5-lipoxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

Role of cytosolic phospholipase A2 in allergic response and parturition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003602012

10.1517/13543771003602012

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference